Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 2/3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cisplatin 18Magnetic Resonance Spectroscopy 14Specimen Handling 12Gemcitabine 12Carboplatin 12pembrolizumab 11Paclitaxel 9Platinum 7Pemetrexed 71,2-diaminocyclohexaneplatinum II citrate 7atezolizumab 6Radiotherapy, Intensity-Modulated 6Radiotherapy 6Radiation 6Nivolumab 6Doxorubicin 6Surgical Procedures, Operative 5Rituximab 5Immunoglobulin G 5Docetaxel 5Disulfides 5Biopsy 5Bevacizumab 5130-nm albumin-bound paclitaxel 5Temozolomide 4Drug Therapy 4Dexamethasone 4Cyclophosphamide 4Cetuximab 4venetoclax 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Hyaluronoglucosaminidase × 30 days × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡